What is the appropriate empiric therapy for cervicitis in non‑pregnant adults?

Cervicitis Treatment

For empiric treatment of cervicitis in non-pregnant adults, treat with azithromycin 1 g orally as a single dose OR doxycycline 100 mg orally twice daily for 7 days, and add concurrent gonorrhea coverage if local prevalence exceeds 5% or the patient is at high risk. 1

Treatment Algorithm

Step 1: Risk Stratification and Decision to Treat Empirically

Provide presumptive antibiotic therapy for Chlamydia trachomatis if the patient meets ANY of these criteria 1:

• Age <25 years
• New or multiple sex partners
• Unprotected sexual intercourse
• Follow-up cannot be ensured
• Only insensitive diagnostic tests available (not NAAT)

If the patient is low-risk and follow-up is reliable with NAAT testing available, you may await test results before treating 1.

Step 2: Primary Antibiotic Regimen

Recommended regimens for chlamydia coverage 1:

• Azithromycin 1 g orally single dose (preferred when compliance is uncertain)
• Doxycycline 100 mg orally twice daily for 7 days (equally effective, less expensive)

Both regimens are equally efficacious 2. Azithromycin offers single-dose directly observed therapy, making it superior in populations with poor compliance or erratic follow-up 2. Doxycycline is more cost-effective when adherence is assured 2.

Step 3: Add Gonorrhea Coverage When Indicated

Add concurrent treatment for N. gonorrhoeae if 1:

• Local gonorrhea prevalence is >5% in your patient population
• Patient is young age
• High facility prevalence

The guidelines emphasize this is particularly important in young patients and high-prevalence settings 1.

Step 4: Treat Co-infections

Screen and treat concomitant infections 1:

• Trichomoniasis: Treat if detected (metronidazole 2 g single dose per sexual assault guidelines 3)
• Bacterial vaginosis (BV): Treat if symptomatic and detected
• Consider testing for T. vaginalis with culture or antigen-based detection if microscopy is negative, as microscopy sensitivity is only ~50% 1

Recent evidence shows that in non-chlamydial/non-gonococcal cervicitis, BV is found in approximately 32% of cases and M. genitalium in 3-7% 4. While M. genitalium testing is not widely available 1, this emerging pathogen should be considered in persistent cases.

Critical Diagnostic Considerations

Before or concurrent with treatment 1:

• Assess for pelvic inflammatory disease (PID) - cervicitis may indicate upper genital tract infection
• Use NAAT testing for C. trachomatis and N. gonorrhoeae (most sensitive/specific, can use cervical or urine samples)
• Check vaginal fluid: >10 WBCs in the absence of trichomoniasis suggests endocervical inflammation from chlamydia or gonorrhea 1

Persistent or Recurrent Cervicitis

If cervicitis persists after initial treatment 1:

1. Reevaluate for reexposure to STDs
2. Reassess vaginal flora for BV
3. Ensure sex partners were evaluated and treated
4. If STD relapse/reinfection excluded and BV absent: management is undefined - repeated antibiotics have unknown value 1
5. Consider gynecologic specialist referral for ablative therapy in clearly symptomatic persistent cases 1

The majority of persistent cervicitis is NOT due to chlamydia or gonorrhea reinfection but may involve abnormal vaginal flora, chemical irritants, or idiopathic inflammation 1.

Partner Management and Follow-up

Sex partner management 1:

• Notify and treat partners for identified or suspected STDs
• Both patient and partners must abstain from intercourse for 7 days after single-dose therapy OR until completion of 7-day regimen 1

Follow-up 1:

• Conduct as recommended for the specific infection treated
• Return for reevaluation if symptoms persist

Special Populations

HIV-infected women 1:

• Use the same treatment regimen as HIV-negative patients
• Treatment is vital because cervicitis increases cervical HIV shedding and may increase transmission to partners 1

Common Pitfalls

• Don't wait for test results in high-risk patients with uncertain follow-up - empiric treatment prevents serious sequelae including PID, ectopic pregnancy, and infertility 1
• Don't forget gonorrhea coverage in high-prevalence settings - the guidelines specifically note this is often overlooked 1
• Don't assume negative microscopy rules out trichomoniasis - sensitivity is only 50% 1
• Don't repeatedly treat persistent cervicitis with antibiotics without reassessing for reinfection or other causes 1